Treatment with bazedoxifene and conjugated estrogens results in regression of endometriosis in a murine model

Biology of Reproduction

Volumn 90, Issue 6, 2014, Pages

  Naqvi, Hanyia ^a   Sakr, Sharif ^a   Presti, Thomas ^a   Krikun, Graciela ^a   Komm, Barry ^b   Taylor, Hugh S ^a,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

^c YALE UNIVERSITY   (United States)

Author keywords

Bazedoxifene (BZA); conjugated estrogen (CE); endometriosis; Hormone receptors; Tissue specific estrogen complex (TSEC)

Indexed keywords

BAZEDOXIFENE; CONJUGATED ESTROGEN; ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; PROGESTERONE RECEPTOR; INDOLE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; ENDOMETRIOSIS; EXPERIMENTAL ENDOMETRIOSIS; EXPERIMENTAL UROGENITAL DISEASE; FEMALE; GENE EXPRESSION; HORMONAL THERAPY; IMMUNOHISTOCHEMISTRY; MOUSE; MOUSE MODEL; NONHUMAN; OVARY CYST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME; TISSUE DIFFERENTIATION; ANIMAL; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; INBRED MOUSE STRAIN; METABOLISM; ORGAN SIZE; OVARY FOLLICLE; PATHOLOGY; RANDOMIZATION; TREATMENT OUTCOME;

ANIMALS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENDOMETRIOSIS; ESTROGEN RECEPTOR ALPHA; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; INDOLES; MICE, INBRED STRAINS; ORGAN SIZE; OVARIAN FOLLICLE; RANDOM ALLOCATION; RECEPTORS, PROGESTERONE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TREATMENT OUTCOME;

EID: 84903763469     PISSN: 00063363     EISSN: 15297268     Source Type: Journal    
DOI: 10.1095/biolreprod.113.114165     Document Type: Article

References (49)

1. Giudice LC, Kao LC. Endometriosis. Lancet 2004; 364(9447):1789-1799.
2. Bulun SE. Endometriosis. N Engl J Med 2009; 360(3):268-279.
3. Kim JJ, Kurita T, Bulun SE. Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocr Rev 2013; 34(1):130-162.
4. Carvalho L, Podgaec S, Bellodi-Privato M, Falcone T, Abrão MS. Role of eutopic endometrium in pelvic endometriosis. J Minim Invasive Gynecol 2011; 18(4):419-427.
5. Allen C, Hopewell S, Prentice A, Gregory D. Nonsteroidal antiinflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev 2009. CD004753.
6. Al Kadri H, Hassan S, Al-Fozan HM, Hajeer A. Hormone therapy for endometriosis and surgical menopause. Cochrane Database Syst Rev 2009. CD005997.
7. Nawathe A, Patwardhan S, Yates D, Harrison GR, Khan KS. Systematic review of the effects of aromatase inhibitors on pain associated with endometriosis. BJOG 2008; 115:818-822.
8. Rodgers AK, Falcone T. Treatment strategies for endometriosis. Expert Opin Pharmacother 2008; 9:243-255.
9. Davis L, Kennedy SS, Moore J, Prentice A. Modern combined oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev 2007. CD001019.
10. Surrey ES. Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show? Curr Opin Obstet Gynecol 2010; 22(4):283-288.
11. Divasta AD, Laufer MR. The use of gonadotropin releasing hormone analogues in adolescent and young patients with endometriosis. Curr Opin Obstet Gynecol 2013; 25(4):287-292.
12. Taylor HS. Designing the ideal selective estrogen receptor modulator-an achievable goal? Menopause 2009; 16(3):609-615.
13. Riggs BL, Hartmann LC. Selective estrogen receptor modulators- mechanisms of action and application to clinical practice. N Engl J Med 2003; 348:618-629.
14. Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, Dowsett M, Forbes JF, Ford L, LaCroix AZ, Mershon J, Mitlak BH, et al. Chemoprevention of Breast Cancer Overview Group. Selective estrogen receptor modulators in prevention of breast cancer: an updated metaanalysis of individual participant data. Lancet 2013; 381(9880): 1827-1834.
15. Pinkerton JV, Goldstein SR. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development. Menopause 2010; 17(3): 642-653.
16. Ethun KF, Wood CE, Cline JM, Register TC, Appt SE, Clarkson TB. Endometrial profile of bazedoxifene acetate alone and in combination with conjugated equine estrogens in a primate model. Menopause 2013; 20(7): 777-784.
17. Archer DF, Pinkerton JV, Utian WH, Menegoci JC, de Villiers TJ, Yuen CK, Levine AB, Chines AA, Constantine GD. Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause 2009; 16(6):1109-1115.
18. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, Rautaharju P, Harper KD. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002; 287(7):847-857.
19. Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HA, Recker RR, Harris ST, Wu W, Genant HK, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002; 87(8):3609-3617.
20. Fuchs-Young R, Glasebrook AL, Short LL, Draper MW, Rippy MK, Cole HW, Magee DE, Termine JD, Bryant HU. Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor. Ann N Y Acad Sci 1995; 761:355-360.
21. Bryant HU, Dere WH. Selective estrogen receptor modulators: an alternative to hormone replacement therapy. Proc Soc Exp Biol Med 1998; 217(1):45-52.
22. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL , Robidoux A, Margolese RG, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006; 295(23):2727-2741.
23. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994; 93:63-69.
24. Yao Z, Shen X, Capodanno I, Donnelly M, Fenyk-Melody J, Hausamann J, Nunes C, Strauss J, Vakerich K. Validation of rat endometriosis model by using raloxifene as a positive control for the evaluation of novel SERM compounds. J Invest Surg 2005; 18:177-183.
25. Stratton P, Sinaii N, Segars J, Koziol D, Wesley R, Zimmer C, Winkel C, Nieman LK. Return of chronic pelvic pain from endometriosis after raloxifene treatment: a randomized controlled trial. Obstet Gynecol 2008; 111:88-96.
26. Genant HK. Bazedoxifene: a new selective estrogen receptor modulator for postmenopausal osteoporosis. Menopause Int 2011; 17(2):44-49.
27. Pickar JH, Yeh I-T, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 2009; 92:1018-1024.
28. Pinkerton JV, Archer DF, Utian WH, Menegoci JC, Levine AB, Chines AA, Constantine GD. Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis. Menopause 2009; 16: 1102-1108.
29. Utian W, Yu H, Bobula J, Mirkin S, Olivier S, Pickar JH. Bazedoxifene/ conjugated estrogens and quality of life in postmenopausal women. Maturitas 2009; 20;63(4):329-335.
30. Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause 2009; 16(6):1116-1124.
31. Stovall DW, Utian WH, Gass ML, Qu Y, Muram D, Wong M, Plouffe L Jr. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. Menopause 2007; 14(3 pt 1):510-517.
32. McCarty KS, Szabo E, Flowers JL, Cox EB, Leight GS, Miller L, Konrath J, Soper JT, Budwit DA, Creasman WT, Seigler HF, McCarty KS Sr. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res 1986; 46: 4244S-4248S.
33. Olive DL, Pritts EA. Treatment of endometriosis. N Engl J Med 2001; 345(4):266-275.
34. Taylor HS, Osteen KG, Bruner-Tran KL, Lockwood CJ, Krikun G, Sokalska A, Duleba AJ. Novel therapies targeting endometriosis. Reprod Sci 2011; 18(9):814-823.
35. Macer ML, Taylor HS. Endometriosis and infertility: a review of the pathogenesis and treatment of endometriosis-associated infertility. Obstet Gynecol Clin North Am 2012; 39(4):535-549.
36. Chwalisz K, Surrey E, Stanczyk FZ. The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropinreleasing hormone agonists in women with endometriosis. Reprod Sci 2012; 19(6):563-571.
37. Hornstein MD, Surrey ES, Weisberg GW, Casino LA. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Obstet Gynecol 1998; 91(1):16-24.
38. Mahutte NG, Arici A. Medical management of endometriosis-associated pain. Obstet Gynecol Clin North Am 2003; 30:133-150.
39. Petraglia F, Hornung D, Seitz C, Faustmann T, Gerlinger C, Luisi S, Lazzeri L, Strowitzki T. Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment. Arch Gynecol Obstet 2012; 285(1):167-173.
40. Vercellini P, Somigliana E, Viganò P, Abbiati A, Barbara G, Crosignani PG. Endometriosis. Drugs 2009; 69(6):649-675.
41. Rogers PA, D'Hooghe TM, Fazleabas A, Giudice LC, Montgomery GW, Petraglia F, Taylor RN. On etiology or lack of understanding: defining future directions for endometriosis research: workshop report from the 2011 World Congress of Endometriosis in Montpellier, France. Reprod Sci 2013; 20(5):483-499.
42. Kulak J Jr, Fischer C, Komm B, Taylor HS. Treatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse model. Endocrinology 2011; 152(8):3226-3232.
43. Mirkin S, Komm BS, Pan K, Chines AA. Effects of bazedoxifene/ conjugated estrogens on endometrial safety and bone in postmenopausal women. Climacteric 2013; 16(3):338-346.
44. Taylor HS, and Ohleth K. Using bazedoxifene plus conjugated estrogens for treating postmenopausal women: a comprehensive review. Menopause 2012; 19(4):479-485.
45. Pinkerton JV, Pickar JH, Racketa J, Mirkin S. Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention. Climacteric 2012; 15:411-418.
46. Komm BS, Mirkin S. Incorporating bazedoxifene/conjugated estrogens into the current paradigm of menopausal therapy. Int J Womens Health 2012; 4:129-140.
47. Berrodin TJ, Chang KCN, Komm BS, Freedman LP, Nagpal S. Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination. Mol Endocrinol 2009; 23(1):74-85.
48. Wardell SE, Nelson ER, Chao CA, McDonnell DP. Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease. Clin Cancer Res 2013; 19(9):2420-2431.
49. Kulak J Jr, Ferriani RA, Komm BS, Taylor HS. Tissue selective estrogen complexes (TSECs) differentially modulate markers of proliferation and differentiation in endometrial cells. Reprod Sci 2013; 20(2):129-137.